Clinical Trial Update: Phase II Study of Anlotinib Versus Sunitinib in Patients With Advanced Renal Cell Carcinoma（RCC） [Phase 2]

View source ↗

Summary

A Phase II clinical trial comparing anlotinib versus sunitinib in patients with advanced renal cell carcinoma; the current status of the study is not disclosed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• Anlotinib (anlotinib)
• Sunitinib (sunitinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: Anlotinib, RCC | Phase 2 | Status: UNKNOWN